Classics in Chemical Neuroscience: Medetomidine

• Published in: ACS chemical neuroscience 2024-11, Vol.15 (21), p.3874-3883
• Main Authors: de Andrade Horn, Pedro, Berida, Tomayo I., Parr, Lauren C., Bouchard, Jacob L., Jayakodiarachchi, Navoda, Schultz, Daniel C., Lindsley, Craig W., Crowley, Morgan L.
• Format: Article
• Language: English
• Subjects: Adrenergic alpha-2 Receptor Agonists - chemistry; Adrenergic alpha-2 Receptor Agonists - pharmacology; Animals; Drug Contamination; Humans; Hypnotics and Sedatives - chemistry; Hypnotics and Sedatives - pharmacology; Illicit Drugs - chemistry; Illicit Drugs - pharmacology; Medetomidine - pharmacology; Review
• ISSN: 1948-7193; 1948-7193
• DOI: 10.1021/acschemneuro.4c00583

Medetomidine is an FDA-approved α2-adrenoreceptor (α2-AR) agonist used as a veterinary sedative due to its analgesic, sedative, and anxiolytic properties. While it is marketed for veterinary use as a racemic mixture under the brand name Domitor, the pharmacologically active enantiomer, dexmedetomidine, is approved for sedation and analgesia in the hospital setting. Medetomidine has recently been detected in the illicit drug supply alongside fentanyl, xylazine, cocaine, and heroin, producing pronounced sedative effects that are not reversed by naloxone. The pharmacological effects along with the low cost of supply and lack of regulation for medetomidine has made it a target for misuse. Since 2022, medetomidine has been found as an adulterant in samples of seized drugs, as well as in toxicological analyses of patients admitted to the emergency department after suspected overdoses across several U.S. states and Canada. This Review will discuss the history, chemistry, structure–activity relationships, drug metabolism and pharmacokinetics (DMPK), pharmacology, and emergence of medetomidine as an adulterant in drug mixtures in the context of the current opioid drug crisis.